Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEISMiC Part B trial of istaroxime in pre-cardiogenic shock due to acute decompensated heart failure
MOH_2022-02-08_010594Phase 2Completed
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of istaroxime in heart failure (HF) and cardiogenic shock (3 arms), sponsored by Windtree Therapeutics, Inc. Started Jun 2021; status: completed.
02
Drugs
istaroxime
03
Conditions
heart failure (HF)cardiogenic shock
Beyond the preview
Go deeper on MOH_2022-02-08_010594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-08_010594.